Objectives: To assess factors affecting physicians' decision on why they did not initiate dual therapy to untreated Type 2 Diabetes Mellitus (T2DM) patients with A1C 7.6-9% per AACE/ACE recommendation. MethOds: Primary care physicians (PCPs) and specialists in the US were asked to provide medical chart reviews for 4 patients who were diagnosed with A1C 7.6-9% and initiated with metformin monotherapy. Physicians rated 22 reasons on a 5-point Likert scale (1-most irrelevant; 5-most relevant) on how relevant each reason was for them in treating a specific patient. Top 5 reasons ( ≥ 50% of physicians rating the reason as 4 or 5) were identified. Association of each reason on physician specialty or age was conducted using mixed-effect model controlling for physician and patient characteristics. Results: 1,235 PCPs and 290 specialists participated the study and provided reviews for 5,995 patients (3,009 young and 2,986 elderly). Four relevant reasons were related to physicians attitudes and beliefs toward metformin monotherapy and dual therapy: R1-"Metformin monotherapy is sufficient to improve glycemic control" (mean[sd]: 3.66[1.1]); R2 -"Monotherapy is easier to handle than dual therapy" (3.53[1.2]); R3-"I believe that monotherapy and changes in lifestyle (e.g. physical activity and dietary change) are enough for hyperglycemia control" (3.47[1.1]); and R4-"I recommend monotherapy before considering dual therapy" (3.75[1.1]). One relevant reason was related to physicians' perception of patients' glycemic level: R5 -"Patient has mild hyperglycemia" " (3.27[1.1]). PCPs rated the four reasons more relevant than specialists (estimate,[95% CI]) (R1: 0.18,[0.05,0.30]; R2: 0.37,[0.24,0.50]; R3: 0.33,[0.20,0.46]; R4: 0.36,[0.23,0.49]. All p< 0.01). Lowering age was also more relevant in the four reasons (R1: -0.04,[-0.06,-0.02]; R2: -0.03,[-0.05,-0.02]; R3: -0.02,[-0.03,0.00], R4: -0.06,[-0.07,-0.04]. All p< 0.02). cOnclusiOns: Guideline non-concordance is related to physicians' attitudes and beliefs toward the therapies and perception of A1C above 8% as "mild". The findings have implications for improving T2DM treatment quality.
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PDB148 longituDinal PattErns of antiDiaBEtEs MEDication PrEscriPtion aMong PrivatEly insurED MEDicarE PatiEnts
Bae J. P, Peng X. , Jiang D. , Zagar A.
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Objectives: To describe changing diabetes treatment pattern among the elderly type 2 diabetes (T2DM) patients during the past 7 years. MethOds: A large retrospective Medicare patient claims data (MarketScan® Medicare) was longitudinally analyzed from 2005 to 2011 to understand T2DM medication use trend. The study included 4 major oral antidiabetic medications (i.e., metformin (MET), sulphonylurea (SU), thiazolidinediones (TZD), and dipeptidyl peptidase 4 inhibitor (DPP-4)) plus injectables (insulin and glucagon-like peptide 1 (GLP-1)) and reported patterns of therapy regimens and trends over time. Results: The study identified 453,045 patients with 1 year enrollment and with T2DM taking one or more antidiabetic medications in 2011, compared to 283,484 patients in 2005. The frequently used mono therapies in 2011 are MET (22.1%), insulin (12.0%) and SU (10.8%), followed by TZD (2.6%), DPP-4 (2.0%), GLP-1 (0.28%). The percentage of patients using MET monotherapy increased from 15.0% in 2005 to 22.1% in 2011, while the percentage of patients using SU alone decreased from 16.6% in 2005 to 10.8% in 2011. Patients taking DPP-4 only increased from 0.03% in 2006 to 2.0% in 2011. Among the combination therapies in 2011, the most popular one was MET+SU (12.2%), followed by MET+DPP-4 (2.9%), MET+SU+DPP-4 (2.8%), MET+TZD (2.8%) and MET+SU+insulin (2.3%). The percentage of patients taking any type of insulin rose by 3.4 on from 24.7% in 2005 to 28.1% in 2011. cOnclusiOns: This study shows changing trends in different classes of diabetes medication in this large sample Medicare patients over time. Continuing research is needed to monitor anitdiabetic treatment pattern change in the future and to understand how these changes are helping to improve diabetes care and outcomes.
PDB149

MEDication aDhErEncE anD sWitching ratEs of PatiEnts With tEstostEronE rEPlacEMEnt thEraPy (trt) in thE unitED statEs
Puenpatom R. A. , Ma L. , Camper S. B. Endo Pharmaceuticals Inc., Malvern, PA, USA Objectives: To assess medication adherence and switching rates of testosterone replacement therapy (TRT) in the US. MethOds: We conducted a retrospective claims database study using the MarketScan® Commercial database from January 2005 through December 2011. The study included men 18-65 years of age who had initiated TRT and were diagnosed with hypogonadism or hypogonadotropic hypogonadism (ICD-9-CM: 257.3 and 257.4). A minimum of 6 months continuous enrollment before and 12 months after the TRT index date was required. Adherence was measured by the Mediation Possession Ratio (MPR) and the Proportion of Days Covered (PDC), with the adherence rate defined as MPR≥ 0.8. The rate of the first switching was summarized by TRT formulation. Results: Of 106,039 patients with hypogonadism, the mean MPR and the mean PDC of any TRT during the 360 days study period was 0.47 and 0.44, respectively. The overall adherence rate over 12 months was 21.4% ranging from 28% (pellets), 19.9% (SAIs), 17.7% (gels), 7.8% (buccal), and 6.6% (patch), respectively. Similarly, the average PDCs were significantly higher for pellets (0.59) compared to gels (0.43), SAIs (0.39), buccal (0.28), and patch (0.27) (P< 0.001). About 13% (n = 13,577) of patients switched from their initial therapy to a different TRT formulation. Patients starting with patch were most likely to switch to a different formulation (39.3%), followed by patients with SAIs (12.1%), pellets/buccal (12.0%), and gels (10.3%). cOnclusiOns: Our study showed low adherence rates of testosterone replacement therapy among hypogonadism patients. The adherence for patients starting on the long-acting testosterone formulation such Simulations estimated 1-and 3-year HbA1c progression for 1000 hypothetical T2DM patients (average 7 (SE 5.1) years post-diagnosis) to obtain the proportion meeting criteria for < 7%, < 8% and > 9% thresholds by bootstrapping the UK Prospective Diabetes Study (UKPDS) 68 equation. UKPDS68 accounts for time, HbA1c in the prior year, drug treatment effect, and baseline A1c. Parameter values for duration of diabetes, baseline HbA1c, and treatment effect were selected from distributions around the mean, and mean values of the latter two were systematically varied to approximate different populations and effects. Results: By 1 year, all NCQA requirements are met when treating patients with alo-pio if average baseline HbA1c is ≤ 8%. At 3 years, all requirements are met in patients with baseline HbA1c ≤ 7.2%, though 8% and 9% threshold requirements are feasible with higher baseline HbA1c. Using a more realistic thiazolidinedione durability assumption (annual rosiglitazone HbA1c increase) instead of UKPDS68, all thresholds are met at 1 year ≤ 8% baseline HbA1c, and at 3 years with ≤ 7.4% baseline HbA1c. The 7% and 8% requirements are met with ≤ 8.2% baseline HbA1c at 1 year; at 3 years, 8% and 9% thresholds can be met with baseline HbA1c ≤ 8-8.2%. cOnclusiOns: The simulations show that clinical thresholds can be met at 1 and 3 years, indicating that alo-pio can be considered for treating an appropriate population from an ACO perspective.
PDB145 rElEvancE of clinical trials to inforM hta: DisParity BEtWEEn hta EviDEncE rEquirEMEnts anD PuBlishED rcts in tyPE 2 DiaBtEtEs MEllitus
King D. T. 1 Objectives: Health technology assessment (HTA) agencies and reimbursement authorities typically require evidence from randomised controlled trials (RCTs) to assess the comparative effectiveness of drugs. For example, for an assessment of the GLP-1 receptor agonist exenatide for management of Type 2 diabetes mellitus (T2DM), the German Federal Joint Committee (G-BA) pre-specified comparators of interest for short-(Byetta®) and long-acting exenatide formulations (Bydureon®) in seven indications. The aim of this research was to assess the availability of direct or indirect evidence for the benefit of exenatide to support an HTA submission to the G-BA. MethOds: A systematic literature review was conducted to identify RCTs comparing exenatide with pharmacological interventions in patients with T2DM. Electronic databases (Medline, Embase, Cochrane library: accessed October 2013) and clinical trial registries were interrogated. Results: Of twenty-nine Byetta® RCTs identified, twenty-seven were inappropriate to provide evidence to the G-BA for the following reasons: use of a non-pre-defined comparator (n= 13), background treatment not requested by G-BA (n= 12), or administration of a non-licenced Byetta® dose (n= 2). The remaining two studies provided direct evidence for two indications. None of the eight Bydureon® RCTs identified were appropriate for direct analysis: use of a non-G-BA-required background treatment (n= 7) or comparator (n= 1). For the five indications where no direct evidence was available, a single RCT investigating Bydureon® was identified which could potentially be used in an indirect comparison against a G-BA required comparator. cOnclusiOns: Despite identification of over thirty RCTs investigating exenatide, most of the available evidence would not be considered appropriate by the G-BA to assess the benefit of exenatide despite having formed the basis for regulatory approval. Regulatory and HTA agencies, reimbursement authorities, and the pharmaceutical industry should be aligned on appropriate RCT design to ensure the generation of relevant evidence, although this may be challenging given the dynamic diabetes treatment environment.
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